Hepatitis C Virus: History and Current Knowledge
Abstract
:1. Introduction
2. The Historical Route of Hepatitis
3. Characteristics of the Virus
4. Viral Infection and Related Diseases
4.1. Viral Hepatitis Pathogenesis
4.2. Virus and Extrahepatic Diseases Manifestations
5. Laboratory Diagnosis
6. Current Treatment Landscape
7. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- World Health Organization (WHO). Hepatitis C. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed on 1 May 2024).
- European Center for Disease Prevention and Control (ECDC) Hepatitis C. Annual Epidemiological Report for 2019. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/AER-Hepatitis-C-2019.pdf (accessed on 1 May 2024).
- Centers for Disease Control and Prevention (CDC) USA. Viral Hepatitis Surveillance (2019). Available online: https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm (accessed on 1 May 2024).
- Centers for Disease Control and Prevention (CDC) USA. Hepatitis C Questions and Answers for Health Professionals. Available online: https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#d7 (accessed on 1 May 2024).
- World Health Organization (WHO). Guidance for Country Validation of Viral Hepatitis Elimination and Path to Elimination. Available online: https://www.who.int/publications/i/item/9789240078635 (accessed on 1 May 2024).
- Galossi, A.; Guarisco, R.; Bellis, L.; Puoti, C. Extrahepatic manifestations of chronic HCV infection. J. Gastrointestin. Liver Dis. 2007, 16, 65–73. [Google Scholar] [PubMed]
- Kc, S.; Murphy, H.; Dixit, S.; Rai, A.; Pradhan, B.; Lagrange-Xelot, M.; Karki, N.; Dureault, A.; Karmacharya, U.; Panthi, S.; et al. Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal. PLoS Negl. Trop. Dis. 2020, 14, e0008931. [Google Scholar] [CrossRef] [PubMed]
- Zignego, A.L.; Gragnani, L.; Giannini, C.; Laffi, G. The hepatitis C virus infection as a systemic disease. Intern. Emerg. Med. 2012, 7, 201–208. [Google Scholar] [CrossRef] [PubMed]
- Santacroce, L.; Losacco, T. Chronic viral diseases of the liver and oncoproteins externalization in hepatocytes. Recenti Prog. Med. 2006, 97, 193–196. [Google Scholar]
- Goldshear, J.L.; Simpson, K.A.; Kral, A.H.; Wenger, L.D.; Bluthenthal, R.N. Novel Routes of Potential Hepatitis C Virus Transmission among People Who Inject Drugs: Secondary Blood Exposures Related to Injection Drug Use. Subst. Use Misuse 2021, 56, 751–757. [Google Scholar] [CrossRef] [PubMed]
- Baré, P. Hepatitis C virus and peripheral blood mononuclear cell reservoirs Patricia Baré. World J. Hepatol. 2009, 1, 67–71. [Google Scholar] [CrossRef]
- Fonseca, J.C. Histórico das hepatites virais [History of viral hepatitis]. Rev. Soc. Bras. Med. Trop. 2010, 43, 322–330. [Google Scholar] [CrossRef] [PubMed]
- Poduri, C.D. Jaundice: A brief historical perspective. Apollo Med. 2016, 13, 76–79. [Google Scholar] [CrossRef]
- Polimeno, L.; Francavilla, A.; Piscitelli, D.; Fiore, M.G.; Polimeno, R.; Topi, S.; Haxhirexha, K.; Ballini, A.; Daniele, A.; Santacroce, L. The role of PIAS3, p-STAT3 and ALR in colorectal cancer: New translational molecular features for an old disease. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 10496–10511. [Google Scholar]
- Charitos, I.A.; Topi, S.; Gagliano-Candela, R.; De Nitto, E.; Polimeno, L.; Montagnani, M.; Santacroce, L. The toxic effects of endocrine disrupting chemicals (EDCs) on gut microbiota: Bisphenol A (BPA). A review. Endocr. Metab. Immune Disord. Drug Targets 2022. ahead of print. [Google Scholar] [CrossRef]
- Sherman, R. Abdominal Pain. In Clinical Methods: The History, Physical, and Laboratory Examinations, 3rd ed.; Walker, H.K., Hall, W.D., Hurst, J.W., Eds.; Butterworths: Boston, MA, USA, 1990; Chapter 86. [Google Scholar]
- MacLagan, N.F. Changing Views on Jaundice. Proc. R. Soc. Med. 1961, 54, 121–126. [Google Scholar] [CrossRef] [PubMed]
- Prioreschi, P. The History of Medicine: Primitive and Ancient Medicine; Edwin Mellen: Lewiston, NY, USA, 1998; pp. 5–672. [Google Scholar]
- Nowak, M.; May, R.M. Virus Dynamics: Mathematical Principles of Immunology and Virology: Mathematical Principles of Immunology and Virology; Chapter 5; Oxford University Press: Oxford, UK, 2000; p. 44. [Google Scholar]
- Paulo, R.F.; Cheng Zhang, Q.C. Liver and gall bladder channel parallels in the Hippocratic Corpus and Huang Di Nei Jing with theoretical considerations. J. Tradit. Complement. Med. 2022, 12, 384–390. [Google Scholar] [CrossRef] [PubMed]
- Choat, M.; Gardner, I. A Coptic Handbook of Ritual Power; Brepols: Turnhout, Belgium, 2014; 160p. [Google Scholar]
- Papavramidou, N.; Fee, E.; Christopoulou-Aletra, H. Jaundice in the Hippocratic Corpus. J. Gastrointest. Surg. 2007, 11, 1728–1731. [Google Scholar] [CrossRef]
- Hippocrates. “Aφορισμοί” (Aphorisms). Chapter 4, Part 62. Available online: http://data.perseus.org/citations/urn:cts:greekLit:tlg0627.tlg012.perseus-grc1:4 (accessed on 1 May 2024).
- Nutton, V. Ancient Medicine, 2nd ed.; Routledge: London, UK, 2012; p. 504. [Google Scholar]
- Aretaeus of Cappadocia “Περί αιτίων και σημείων οξέων παθών” (De causis et signis acutorum morborum), “περὶ Ἰκτέρου,” Κεφ. Ιε (On Jaundice or Icterus Vol. 2, Chapter XV). Available online: http://data.perseus.org/citations/urn:cts:greekLit:tlg0719.tlg002.perseus-grc1:1.15 (accessed on 2 May 2024).
- Topi, S.; Santacroce, L.; Bottalico, L.; Ballini, A.; Inchingolo, A.D.; Dipalma, G.; Charitos, I.A.; Inchingolo, F. Gastric Cancer in History: A Perspective Interdisciplinary Study. Cancers 2020, 12, 264. [Google Scholar] [CrossRef]
- Skaltsa, E. History of Pharmacy; Association of Greek Academic Libraries: Kallipos, Greece, 2015; pp. 4–323. [Google Scholar]
- Al-Mahtab, M.; Roy, P.P.; Khan, M.S.I.; Akbar, S.M. Nobel Prize for the Discovery of Hepatitis B and C: A Brief History in Time. Euroasian J. Hepatogastroenterol. 2020, 10, 98–100. [Google Scholar] [CrossRef]
- Tang, H.; Grisé, H. Cellular and molecular biology of HCV infection and hepatitis. Clin. Sci. 2009, 117, 49–65. [Google Scholar] [CrossRef] [PubMed]
- Alter, H.J. The gordon wilson lecture: The hepatitis c virus: From hippocrates to cure. Trans. Am. Clin. Climatol. Assoc. 2019, 130, 104–118. [Google Scholar]
- Hu, W.; Zhang, C.; Shi, J.J.; Zhang, J.Y.; Wang, F.S. Hepatitis C: Milestones from discovery to clinical cure. Mil. Med. Res. 2020, 7, 59. [Google Scholar] [CrossRef]
- Ghany, M.G.; Lok, A.S.F.; Dienstag, J.L.; Feinstone, S.M.; Hoofnagle, J.H.; Jake Liang, T.; Seeff, L.B.; Cohen, D.E.; Bezerra, J.A.; Chung, R.T. The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. Hepatology 2021, 74, 2813–2823. [Google Scholar] [CrossRef]
- Gretch, D.R. Introduction. In Hepatitis C Viruses: Genomes and Molecular Biology; Horizon Bioscience: Norfolk, UK, 2006. [Google Scholar]
- Smith, D.B.; Becher, P.; Bukh, J.; Gould, E.A.; Meyers, G.; Monath, T.; Muerhoff, A.S.; Pletnev, A.; Rico-Hesse, R.; Stapleton, J.T.; et al. Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. J. Gen. Virol. 2016, 97, 2894–2907. [Google Scholar] [CrossRef]
- Morozov, V.A.; Lagaye, S. Hepatitis C virus: Morphogenesis, infection, and therapy. World J. Hepatol. 2018, 10, 186–212. [Google Scholar] [CrossRef] [PubMed]
- Breitinger, U.; Farag, N.S.; Ali, N.K.M.; Ahmed, M.; El-Azizi, M.A.; Breitinger, H.G. Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels. J. Gen. Virol. 2021, 102, 001571. [Google Scholar] [CrossRef] [PubMed]
- Echeverría, N.; Moratorio, G.; Cristina, J.; Moreno, P. Hepatitis C virus genetic variability and evolution. World J. Hepatol. 2015, 7, 831–845. [Google Scholar] [CrossRef] [PubMed]
- Li, C.F.; Tsao, S.M.; Liao, H.H.; Chen, S.C.; Lee, Y.T. Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma: A meta-analysis. Medicine 2020, 99, e22435. [Google Scholar] [CrossRef]
- Li, Q.R.; Zhang, C.J.; Xiong, Y.L.; Zhu, Y.; Tan, Z.X.; Hu, Y.J.; Yuan, J.; Wang, X.H. Long-term assessment of relapse and associ-ated risk factors in chronic hepatitis C patients treated with interferon and ribavirin. Chin. J. Hepatol. 2012, 20, 353–356. (In Chinese) [Google Scholar] [CrossRef]
- Domingo, E.; Sheldon, J.; Perales, C. Viral quasispecies evolution. Microbiol. Mol. Biol. Rev. 2012, 76, 159–216. [Google Scholar] [CrossRef]
- Tarr, A.W.; Khera, T.; Hueging, K.; Sheldon, J.; Steinmann, E.; Pietschmann, T.; Brown, R.J. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses 2015, 7, 3995–4046. [Google Scholar] [CrossRef] [PubMed]
- Durante Mangoni, E.; Forton, D.M.; Ruggiero, G.; Karayiannis, P. Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations. J. Med. Virol. 2003, 70, 62–73. [Google Scholar] [CrossRef]
- Hedskog, C.; Parhy, B.; Chang, S.; Zeuzem, S.; Moreno, C.; Shafran, S.D.; Borgia, S.M.; Asselah, T.; Alric, L.; Abergel, A.; et al. Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. Open Forum Infect. Dis. 2019, 6, ofz076. [Google Scholar] [CrossRef]
- Niepmann, M.; Gerresheim, G.K. Hepatitis C Virus Translation Regulation. Int. J. Mol. Sci. 2020, 21, 2328. [Google Scholar] [CrossRef]
- Friebe, P.; Bartenschlager, R. Genetic analysis of sequences in the 3′ nontranslated region of hepatitis C virus that are important for RNA replication. J. Virol. 2002, 76, 5326–5338. [Google Scholar] [CrossRef] [PubMed]
- Alzahrani, N.; Wu, M.J.; Shanmugam, S.; Yi, M. Delayed by Design: Role of Suboptimal Signal Peptidase Processing of Viral Structural Protein Precursors in Flaviviridae Virus Assembly. Viruses 2020, 12, 1090. [Google Scholar] [CrossRef] [PubMed]
- Lavie, M.; Goffard, A.; Dubuisson, J. HCV Glycoproteins: Assembly of a Functional E1–E2 Heterodimer. In Hepatitis C Viruses: Genomes and Molecular Biology; Tan, S.L., Ed.; Horizon Bioscience: Norfolk, UK, 2006; Chapter 4. [Google Scholar]
- Pascut, D.; Hoang, M.; Nguyen, N.N.Q.; Pratama, M.Y.; Tiribelli, C. HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. Cancers 2021, 13, 2485. [Google Scholar] [CrossRef] [PubMed]
- Mirandola, S.; Bowman, D.; Hussain, M.M.; Alberti, A. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). Nutr. Metab. 2010, 7, 13. [Google Scholar] [CrossRef] [PubMed]
- Bufo, P.; Losacco, T.; Latorre, V.; Parisi, G.; Santacroce, L. Assessment of hepatocyte AgNORs expression in chronic hepatopathy. Clin. Ter. 2000, 151, 417–419. [Google Scholar] [PubMed]
- Masalova, O.V.; Lesnova, E.I.; Solyev, P.N.; Zakirova, N.F.; Prassolov, V.S.; Kochetkov, S.N.; Ivanov, A.V.; Kushch, A.A. Modulation of Cell Death Pathways by Hepatitis C Virus Proteins in Huh7.5 Hepatoma Cells. Int. J. Mol. Sci. 2017, 18, 2346. [Google Scholar] [CrossRef] [PubMed]
- Vieyres, G.; Dubuisson, J.; Pietschmann, T. Incorporation of hepatitis C virus E1 and E2 glycoproteins: The keystones on a peculiar virion. Viruses 2014, 6, 1149–1187. [Google Scholar] [CrossRef] [PubMed]
- Breitinger, U.; Ali, N.K.M.; Sticht, H.; Breitinger, H.G. Inhibition of SARS CoV Envelope Protein by Flavonoids and Classical Viroporin Inhibitors. Front. Microbiol. 2021, 12, 692423. [Google Scholar] [CrossRef]
- To, J.; Torres, J. Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins. In Virus Protein and Nucleoprotein Complexes. Subcellular Biochemistry; Harris, J., Bhella, D., Eds.; Springer: Singapore, 2018; Volume 88. [Google Scholar]
- Lorenz, I.C. The Hepatitis C Virus Nonstructural Protein 2 (NS2): An Up-and-Coming Antiviral Drug Target. Viruses 2010, 2, 1635–1646. [Google Scholar] [CrossRef]
- Nasar, S.; Rashid, N.; Iftikhar, S. Dengue proteins with their role in pathogenesis, and strategies for developing an effective anti-dengue treatment: A review. J. Med. Virol. 2020, 92, 941–955. [Google Scholar] [CrossRef]
- Ostrowska, N.; Feig, M.; Trylska, J. Crowding affects structural dynamics and contributes to membrane association of the NS3/4A complex. Biophys. J. 2021, 120, 3795–3806. [Google Scholar] [CrossRef]
- Tanaka, T.; Kuroda, K.; Ikeda, M.; Wakita, T.; Kato, N.; Makishima, M. Hepatitis C virus NS4B targets lipid droplets through hydrophobic residues in the amphipathic helices. J. Lipid Res. 2013, 54, 881–892. [Google Scholar] [CrossRef] [PubMed]
- Tabata, K.; Neufeldt, C.J.; Bartenschlager, R. Hepatitis C Virus Replication. Cold Spring Harb. Perspect. Med. 2020, 10, a037093. [Google Scholar] [CrossRef] [PubMed]
- Yu, G.Y.; He, G.; Li, C.Y.; Tang, M.; Grivennikov, S.; Tsai, W.T.; Wu, M.S.; Hsu, C.W.; Tsai, Y.; Wang, L.H.; et al. Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. Mol. Cell. 2012, 8, 313–321. [Google Scholar] [CrossRef] [PubMed]
- Heo, T.H.; Lee, S.M.; Bartosch, B.; Cosset, F.L.; Kang, C.Y. Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein. Virus Res. 2006, 121, 58–64. [Google Scholar] [CrossRef] [PubMed]
- Fénéant, L.; Levy, S.; Cocquerel, L. CD81 and hepatitis C virus (HCV) infection. Viruses 2014, 6, 535–572. [Google Scholar] [CrossRef] [PubMed]
- Bankwitz, D.; Vieyres, G.; Hueging, K.; Bitzegeio, J.; Doepke, M.; Chhatwal, P.; Haid, S.; Catanese, M.T.; Zeisel, M.B.; Nicosia, A.; et al. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins. J. Virol. 2014, 88, 12644–12655. [Google Scholar] [CrossRef] [PubMed]
- Khoo, U.S.; Chan, K.Y.; Chan, V.S.; Lin, C.L. DC-SIGN and L-SIGN: The SIGNs for infection. J. Mol. Med. 2008, 86, 861–874. [Google Scholar] [CrossRef] [PubMed]
- Du, L.; Tang, H. An insight into the molecular characteristics of hepatitis C virus for clinicians. Saudi Med. J. 2016, 37, 483–491. [Google Scholar] [CrossRef]
- Woo, J.; Choi, Y. Biomarkers in Detection of Hepatitis C Virus Infection. Pathogens 2024, 13, 331. [Google Scholar] [CrossRef]
- Lai, C.K.; Jeng, K.S.; Machida, K.; Lai, M.M. Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A. J. Virol. 2008, 82, 8838–8848. [Google Scholar] [CrossRef] [PubMed]
- Strosberg, A.D.; Kota, S.; Takahashi, V.; Snyder, J.K.; Mousseau, G. Core as a novel viral target for hepatitis C drugs. Viruses 2010, 2, 1734–1751. [Google Scholar] [CrossRef] [PubMed]
- Lamp, B.; Riedel, C.; Wentz, E.; Tortorici, M.A.; Rümenapf, T. Autocatalytic cleavage within classical swine fever virus NS3 leads to a functional separation of protease and helicase. J. Virol. 2013, 87, 11872–11883. [Google Scholar] [CrossRef] [PubMed]
- Paul, D.; Hoppe, S.; Saher, G.; Krijnse-Locker, J.; Bartenschlager, R. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J. Virol. 2013, 87, 10612–10627. [Google Scholar] [CrossRef] [PubMed]
- Dearborn, A.D.; Marcotrigiano, J. Hepatitis C Virus Structure: Defined by What It Is Not. Cold Spring Harb. Perspect. Med. 2020, 10, a036822. [Google Scholar] [CrossRef] [PubMed]
- Lim, H.K.; Jeffrey, G.P.; Ramm, G.A.; Soekmadji, C. Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles. Front. Cell Infect. Microbiol. 2010, 10, 587628. [Google Scholar] [CrossRef] [PubMed]
- Schaefe, T.J.; John, S. Acute Hepatitis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2021. [Google Scholar]
- Rosu, A.F.; Freitas, C.; Marinho, R.T.; Velosa, J. Spontaneous Cure of Acute Hepatitis C. Curr. Health Sci. J. 2015, 41, 375–378. [Google Scholar]
- Lingala, S.; Ghany, M.G. Natural History of Hepatitis C. Gastroenterol. Clin. N. Am. 2015, 44, 717–734. [Google Scholar] [CrossRef]
- Giannini, E.G.; Testa, R.; Savarino, V. Liver enzyme alteration: A guide for clinicians. CMAJ 2005, 172, 367–379. [Google Scholar] [CrossRef]
- Grebely, J.; Prins, M.; Hellard, M.; Cox, A.L.; Osburn, W.O.; Lauer, G.; Page, K.; Lloyd, A.R.; Dore, G.J.; International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine. Lancet Infect. Dis. 2012, 12, 408–414. [Google Scholar] [CrossRef]
- Baskic, D.; Vukovic, V.; Popovic, S.; Jovanovic, D.; Mitrovic, S.; Djurdjevic, P.; Avramovic, D.; Arsovic, A.; Bankovic, D.; Cukic, J.; et al. Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution. PLoS ONE. 2019, 14, e0219508, Erratum in PLoS ONE 2019, 14, e0221142. [Google Scholar]
- Mohamadnejad, M.; Tavangar, S.M.; Sotoudeh, M.; Kosari, F.; Khosravi, M.; Geramizadeh, B.; Montazeri, G.; Estakhri, A.; Mirnasseri, M.M.; Fazlollahi, A.R.; et al. Histopathological Study of Chronic Hepatitis B: A Comparative Study of Ishak and METAVIR Scoring Systems. Int. J. Organ. Transplant. Med. 2010, 1, 171–176. [Google Scholar] [CrossRef] [PubMed]
- Krishna, M. Histological Grading and Staging of Chronic Hepatitis. Clin. Liver Dis. 2021, 17, 222–226. [Google Scholar] [CrossRef] [PubMed]
- Dustin, L.B.; Cashman, S.B.; Laidlaw, S.M. Immune control, and failure in HCV infection–tipping the balance. J. Leukoc. Biol. 2014, 96, 535–548. [Google Scholar] [CrossRef] [PubMed]
- Axley, P.; Ahmed, Z.; Ravi, S.; Singal, A.K. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J. Clin. Transl. Hepatol. 2018, 6, 79–84. [Google Scholar] [CrossRef] [PubMed]
- Masia, R.; Misdraji, J. Liver and Bile Duct Infections. Diagn. Pathol. Infect. Dis. 2018, 272–322. [Google Scholar]
- Jothimani, D.; Venugopal, R.; Vij, M.; Rela, M. Post liver transplant recurrent and de novo viral infections. Best Pract. Res. Clin. Gastroenterol. 2020, 46–47, 101689. [Google Scholar] [CrossRef]
- Mohanraj, B.S.; Rangnekar, A.S.; Timpone, J.G., Jr. Infections in Liver Transplantation. Princ. Pract. Transplant. Infect. Dis. 2018, 41–72. [Google Scholar]
- Kwong, A.J.; Kim, W.R.; Lake, J.R.; Smith, J.M.; Schladt, D.P.; Skeans, M.A.; Noreen, S.M.; Foutz, J.; Booker, S.E.; Cafarella, M.; et al. OPTN/SRTR 2019 Annual Data Report: Liver. Am. J. Transplant. 2021, 21, 208–315. [Google Scholar] [CrossRef] [PubMed]
- Lippolis, R.; Gnocchi, D.; Santacroce, L.; Siciliano, R.A.; Mazzeo, M.F.; Scacco, S.; Sabbà, C.; Mazzocca, A.A. distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2020, 526, 1150–1156. [Google Scholar] [CrossRef]
- Finotti, M.; Vitale, A.; Volk, M.; Cillo, U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert. Rev. Gastroenterol. Hepatol. 2020, 14, 885–900. [Google Scholar] [CrossRef] [PubMed]
- Grassi, A.; Ballardini, G. Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem. World J. Gastroenterol. 2014, 20, 11095–11115. [Google Scholar] [CrossRef] [PubMed]
- Peters, M.G.; Kottilil, S.; Terrault, N.; Amara, D.; Husson, J.; Huprikar, S.; Florman, S.; Sulkowski, M.S.; Durand, C.M.; Luetkemeyer, A.F.; et al. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. Am. J. Transplant. 2021, 21, 1780–1788. [Google Scholar] [CrossRef] [PubMed]
- Albekairy, A.M.; Abdel-Razaq, W.S.; Alkatheri, A.M.; Debasi, T.M.A.; Otaibi, N.E.A.; Qandil, A.M. The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation. Int. J. Health Sci. 2018, 12, 78–87. [Google Scholar]
- Manzia, T.M.; Angelico, R.; Ciano, P.; Mugweru, J.; Owusu, K.; Sforza, D.; Toti, L.; Tisone, G. Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients. World J. Gastroenterol. 2014, 20, 12217–12225. [Google Scholar] [CrossRef] [PubMed]
- Lai, J.C.; Verna, E.C.; Brown, R.S., Jr.; O’Leary, J.G.; Trotter, J.F.; Forman, L.M.; Duman, J.D.; Foster, R.G.; Stravitz, R.T.; Terrault, N.A.; et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011, 54, 418–424. [Google Scholar] [CrossRef] [PubMed]
- Layden, J.E.; Cotler, S.; Brown, K.A.; Lucey, M.R.; Te, H.S.; Eswaran, S.; Fimmel, C.; Layden, T.J.; Clark, N.M. Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation 2012, 94, 178–184. [Google Scholar] [CrossRef] [PubMed]
- Kemmer, N. Ethnic disparities in liver transplantation. Gastroenterol. Hepatol. 2011, 7, 302–307. [Google Scholar]
- Caso-Maestro, O.; Jiménez-Romero, C.; Justo-Alonso, I.; Calvo-Pulido, J.; Lora-Pablos, D.; Marcacuzco-Quinto, A.; Cambra-Molero, F.; García-Sesma, A.; Pérez-Flecha, M.; Muñoz-Arce, C.; et al. Analyzing predictors of graft survival in patients undergoing liver transplantation with donors aged 70 years and over. World J. Gastroenterol. 2018, 24, 5391–5402. [Google Scholar] [CrossRef]
- Tsoulfas, G.; Goulis, I.; Giakoustidis, D.; Akriviadis, E.; Agorastou, P.; Imvrios, G.; Papanikolaou, V. Hepatitis C and liver transplantation. Hippokratia 2009, 13, 211–215. [Google Scholar]
- Mazzaro, C.; Quartuccio, L.; Adinolfi, L.E.; Roccatello, D.; Pozzato, G.; Nevola, R.; Tonizzo, M.; Gitto, S.; Andreone, P.; Gattei, V. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses 2021, 13, 2249. [Google Scholar] [CrossRef] [PubMed]
- Negro, F. Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. Cold Spring Harb. Perspect. Med. 2020, 10, a036921. [Google Scholar] [CrossRef] [PubMed]
- El Hadi, H.; Di Vincenzo, A.; Vettor, R.; Rossato, M. Relationship between Heart Disease and Liver Disease: A Two-Way Street. Cells. 2020, 9, 567. [Google Scholar] [CrossRef]
- EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis. Available online: https://easl.eu/wp-content/uploads/2018/10/decompensated-cirrhosis-English-report.pdf (accessed on 1 August 2023).
- Youssef, S.S.; Elemeery, M.N.; Eldein, S.S.; Ghareeb, D.A. Silencing HCV Replication in Its Reservoir. Open Access Maced. J. Med. Sci. 2018, 6, 1965–1971. [Google Scholar] [CrossRef] [PubMed]
- Barría, M.I.; Vera-Otarola, J.; León, U.; Vollrath, V.; Marsac, D.; Riquelme, A.; López-Lastra, M.; Soza, A. Influence of extrahepatic viral infection on the natural history of hepatitis C. Ann. Hepatol. 2008, 7, 136–143. [Google Scholar] [CrossRef]
- Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wölk, B.; Tellinghuisen, T.L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A.; et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623–626. [Google Scholar] [CrossRef]
- Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Kräusslich, H.G.; Mizokami, M.; et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791–796. [Google Scholar] [CrossRef]
- Roque-Afonso, A.M.; Ducoulombier, D.; Di Liberto, G.; Kara, R.; Gigou, M.; Dussaix, E.; Samuel, D.; Féray, C. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J. Virol. 2005, 79, 6349–6357. [Google Scholar] [CrossRef]
- Mercuri, L.; Thomson, E.C.; Hughes, J.; Karayiannis, P. Quasispecies Changes with Distinctive Point Mutations in the Hepatitis C Virus Internal Ribosome Entry Site (IRES) Derived from PBMCs and Plasma. Adv. Virol. 2018, 2018, 4835252. [Google Scholar] [CrossRef]
- Pawełczyk, A.; Kubisa, N.; Jabłońska, J.; Bukowska-Ośko, I.; Caraballo Cortes, K.; Fic, M.; Laskus, T.; Radkowski, M. Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+. Virol. J. 2013, 10, 346. [Google Scholar] [CrossRef]
- Khattab, M.A.; Zakaria, Y.; Sadek, E.; Abd El Fatah, A.S.; Fouad, M.; Khattab, M.; Moness, H.M.; Adel, N.M.; Ahmed, E. Detection of hepatitis C virus (HCV) RNA in the peripheral blood mononuclear cells of HCV-infected patients following sustained virologic response. Clin. Exp. Med. 2022, 23, 131–140. [Google Scholar] [CrossRef] [PubMed]
- Wróblewska, A.; Bielawski, K.P.; Sikorska, K. Occult Infection with Hepatitis C Virus: Looking for Clear-Cut Boundaries and Methodological Consensus. J. Clin. Med. 2021, 10, 5874. [Google Scholar] [CrossRef] [PubMed]
- Fiji, K.; Hino, K.; Okazaki, M.; Okuda, M.; Kondoh, S.; Okita, K. Differences in hypervariable region 1 quasispecies of hepatitis C virus between human serum and peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 1996, 225, 771–776. [Google Scholar] [CrossRef] [PubMed]
- Patel, A.M.; Liu, Y.S.; Davies, S.P.; Brown, R.M.; Kelly, D.A.; Scheel-Toellner, D.; Reynolds, G.M.; Stamataki, Z. The Role of B Cells in Adult and Paediatric Liver Injury. Front. Immunol. 2021, 12, 729143. [Google Scholar] [CrossRef] [PubMed]
- Rahimi, N. C-type Lectin CD209L/L-SIGN and CD209/DC-SIGN: Cell Adhesion Molecules Turned to Pathogen Recognition Receptors. Biology 2020, 10, 1. [Google Scholar] [CrossRef] [PubMed]
- Ducoulombier, D.; Roque-Afonso, A.M.; Di Liberto, G.; Penin, F.; Kara, R.; Richard, Y.; Dussaix, E.; Féray, C. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004, 39, 817–825. [Google Scholar] [CrossRef] [PubMed]
- Zignego, A.L.; Giannelli, F.; Marrocchi, M.E.; Mazzocca, A.; Ferri, C.; Giannini, C.; Monti, M.; Caini, P.; Villa, G.L.; Laffi, G.; et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000, 31, 474–479. [Google Scholar] [CrossRef] [PubMed]
- Jadali, Z. Hepatitis C virus cryoglobulinemia and non-hodgkin lymphoma. Hepat. Mon. 2012, 12, 85–91. [Google Scholar] [CrossRef]
- Dai, B.; Chen, A.Y.; Corkum, C.P.; Peroutka, R.J.; Landon, A.; Houng, S.; Muniandy, P.A.; Zhang, Y.; Lehrmann, E.; Mazan-Mamczarz, K.; et al. (Hepatitis C virus upregulates B-cell receptor signaling: A novel mechanism for HCV-associated B-cell lymphoproliferative disorders. Oncogene 2016, 35, 2979–2990. [Google Scholar] [CrossRef]
- Napodano, C.; Gulli, F.; Rapaccini, G.L.; Marino, M.; Basile, U. Cryoglobulins: Identification, classification, and novel biomarkers of mysterious proteins. Adv. Clin. Chem. 2021, 104, 299–340. [Google Scholar]
- Walewski, J.L.; Keller, T.R.; Stump, D.D.; Branch, A.D. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 2001, 7, 710–721. [Google Scholar] [CrossRef] [PubMed]
- Sautto, G.; Mancini, N.; Clementi, M.; Burioni, R. Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII). Viruses 2012, 4, 2924–2944. [Google Scholar] [CrossRef] [PubMed]
- Mazzaro, C.; Dal Maso, L.; Mauro, E.; Gattei, V.; Ghersetti, M.; Bulian, P.; Moratelli, G.; Grassi, G.; Zorat, F.; Pozzato, G. Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases. Diseases 2018, 6, 35. [Google Scholar] [CrossRef] [PubMed]
- Mazzaro, C.; Mauro, E.; Ermacora, A.; Doretto, P.; Fumagalli, S.; Tonizzo, M.; Toffolutti, F.; Gattei, V. Hepatitis C virus-related cryoglobulinemic vasculitis. Minerva Medica 2021, 112, 175–187. [Google Scholar] [CrossRef] [PubMed]
- Franzin, F.; Efremov, D.G.; Pozzato, G.; Tulissi, P.; Batista, F.; Burrone, O.R. Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br. J. Haematol. 1995, 90, 548–552. [Google Scholar] [CrossRef] [PubMed]
- Kayode-Ajala, F.; Ejikeme, C.; Picone, J.; Sanyal, A. A Case of Hepatitis C Related Mixed Cryoglobulinemia Syndrome. J. Community Hosp. Intern. Med. Perspect. 2022, 12, 53–56. [Google Scholar] [CrossRef] [PubMed]
- Cacoub, P.; Gragnani, L.; Comarmond, C.; Zignego, A.L. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig. Liver Dis. 2014, 46, S165–S173. [Google Scholar] [CrossRef]
- Zignego, A.L.; Gragnani, L.; Piluso, A.; Sebastiani, M.; Giuggioli, D.; Fallahi, P.; Antonelli, A.; Ferri, C. Virus-driven autoimmunity and lymphoproliferation: The example of HCV infection. Expert. Rev. Clin. Immunol. 2015, 11, 15–31. [Google Scholar] [CrossRef]
- Zignego, A.L.; Giannini, C.; Gragnani, L. HCV and lymphoproliferation. Clin. Dev. Immunol. 2012, 2012, 980942. [Google Scholar] [CrossRef]
- Gragnani, L.; Piluso, A.; Giannini, C.; Caini, P.; Fognani, E.; Monti, M.; Petrarca, A.; Ranieri, J.; Razzolini, G.; Froio, V.; et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and Fcγ receptors. Arthritis Rheum. 2011, 63, 1446–1451. [Google Scholar] [CrossRef]
- Charles, E.D.; Brunetti, C.; Marukian, S.; Ritola, K.D.; Talal, A.H.; Marks, K.; Jacobson, I.M.; Rice, C.M.; Dustin, L.B. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011, 117, 5425–5437. [Google Scholar] [CrossRef]
- Ramakrishnaiah, V.; Thumann, C.; Fofana, I.; Habersetzer, F.; Pan, Q.; de Ruiter, P.E.; Willemsen, R.; Demmers, J.A.; Stalin, R.V.; Jenster, G.; et al. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc. Natl. Acad. Sci. USA 2013, 110, 13109–13113. [Google Scholar] [CrossRef] [PubMed]
- Machida, K.; Liu, J.C.; McNamara, G.; Levine, A.; Duan, L.; Lai, M.M. Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway. J. Virol. 2009, 83, 12590–12600. [Google Scholar] [CrossRef]
- Szczepański, T.; Pongers-Willemse, M.J.; Langerak, A.W.; Harts, W.A.; Wijkhuijs, A.J.; van Wering, E.R.; van Dongen, J.J. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999, 93, 4079–4085. [Google Scholar] [CrossRef]
- Libra, M.; Gloghini, A.; Malaponte, G.; Gangemi, P.; De Re, V.; Cacopardo, B.; Spandidos, D.A.; Nicoletti, F.; Stivala, F.; Zignego, A.L.; et al. Association of t (14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J. Hepatol. 2008, 49, 170–174. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Yao, F.; Xiao, Z.; Sun, Y.; Ma, L. MicroRNAs and metastasis: Small RNAs play big roles. Cancer Metastasis Rev. 2018, 37, 5–15. [Google Scholar] [CrossRef]
- Zignego, A.L.; Giannini, C.; Ferri, C. Hepatitis C virus-related lymphoproliferative disorders: An overview. World J. Gastroenterol. 2007, 13, 2467–2478. [Google Scholar] [CrossRef] [PubMed]
- Gullim, F.; Marino, M.; Napodano, C.; Pocino, K.; Pandolfi, F.; Gasbarrini, A.; Rapaccini, G.L.; Basile, U. Biomarkers in HCV-related mixed cryoglobulinemia patients with non-hodgkin lymphoma. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 8067–8074. [Google Scholar]
- Nazary, K.; Anwar, S.; Choudhary, A.Y.; Malla, D.; Hafizyar, F.; Talpur, A.S.; Fatima, F.; Khan, M. Prevalence of Thyroid Dysfunction in Patients with Hepatitis C. Cureus 2021, 13, e18289. [Google Scholar] [CrossRef] [PubMed]
- Tran, A.; Quaranta, J.F.; Benzaken, S.; Thiers, V.; Chau, H.T.; Hastier, P.; Regnier, D.; Dreyfus, G.; Pradier, C.; Sadoul, J.L. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993, 18, 253–257. [Google Scholar] [CrossRef]
- Ferri, C.; Colaci, M.; Fallahi, P.; Ferrari, S.M.; Antonelli, A.; Giuggioli, D. Thyroid Involvement in Hepatitis C Virus-Infected Patients with/without Mixed Cryoglobulinemia. Front. Endocrinol. 2017, 8, 159. [Google Scholar] [CrossRef]
- Jadali, Z. Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy. Indian J. Endocrinol. Metab. 2013, 17, 69–75. [Google Scholar] [CrossRef]
- Desailloud, R.; Hober, D. Viruses, and thyroiditis: An update. Virol. J. 2009, 6, 5. [Google Scholar] [CrossRef] [PubMed]
- Yang, Z.; Liang, Y.; Zhong, R. Is identification of anti-SSA and/or -SSB antibodies necessary in serum samples referred for antinuclear antibodies testing? J. Clin. Lab. Anal. 2012, 26, 447–451. [Google Scholar] [CrossRef]
- Argyropoulou, O.D.; Pezoulas, V.; Chatzis, L.; Critselis, E.; Gandolfo, S.; Ferro, F.; Quartuccio, L.; Donati, V.; Treppo, E.; Bassoli, C.R.; et al. Cryoglobulinemic vasculitis in primary Sjögren’s Syndrome: Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease. Semin. Arthritis Rheum. 2020, 50, 846–853. [Google Scholar] [CrossRef]
- Alhazmi, A.A.; Almuflihi, A.; Aly, M.M.; Mohammed, A.; Alshehri, A. Hepatitis C-induced Sjögren’s Syndrome with Positive Serology: A Case Report. Cureus 2021, 13, e20091. [Google Scholar] [CrossRef]
- Bhattacharya, D.; Aronsohn, A.; Price, J.; Lo Re, V.; AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis. 2023, ciad319. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, H.; Tsukamoto, M.; Nagasawa, Y.; Kitamura, N.; Shimizu, T.; Kawakami, A.; Nagata, K.; Takei, M. Does HTLV-1 Infection Show Phenotypes Found in Sjögren’s Syndrome? Viruses 2022, 14, 100. [Google Scholar] [CrossRef] [PubMed]
- Ramos-Casals, M.; Garcia-Carrasco, M.; Cervera, R.; Font, J. Is hepatitis C virus a sialotropic virus? Am. J. Pathol. 2001, 159, 1593–1594. [Google Scholar] [CrossRef]
- Aliannejad, R.; Ghanei, M. Hepatitis C and pulmonary fibrosis: Hepatitis C and pulmonary fibrosis. Hepat. Mon. 2011, 11, 71–73. [Google Scholar]
- Yin, Q.; Strong, M.J.; Zhuang, Y.; Flemington, E.K.; Kaminski, N.; De Andrade, J.A.; Lasky, J.A. Assessment of viral RNA in idiopathic pulmonary fibrosis using RNA-seq. BMC Pulm. Med. 2020, 20, 81. [Google Scholar] [CrossRef] [PubMed]
- Arase, Y.; Suzuki, F.; Suzuki, Y.; Akuta, N.; Kobayashi, M.; Kawamura, Y.; Yatsuji, H.; Sezaki, H.; Hosaka, T.; Hirakawa, M.; et al. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J. Gastroenterol. 2008, 14, 5880–5886. [Google Scholar] [CrossRef] [PubMed]
- To-Figueras, J. Association between hepatitis C virus and porphyria cutanea tarda. Mol. Genet. Metab. 2019, 128, 282–287. [Google Scholar] [CrossRef] [PubMed]
- Quansah, R.; Cooper, C.J.; Said, S.; Bizet, J.; Paez, D.; Hernandez, G.T. Hepatitis C- and HIV-induced porphyria cutanea tarda. Am. J. Case Rep. 2014, 15, 35–40. [Google Scholar]
- Barajas, L.; Steuer, M.; Amerson, E. Variable clinical course of lichen planus following hepatitis C cure with direct-acting antivirals: A case series and literature review. J. Am. Acad. Dermatol. 2021, 84, 1142–1146. [Google Scholar] [CrossRef] [PubMed]
- Morgado-Carrasco, D.; Combalia, A.; Fustà-Novell, X.; Mascaró, J.M., Jr.; Iranzo, P. Aggressive erosive lichen planus associated with hepatitis C responding to sofosbuvir/ledipasvir treatment. Indian J. Dermatol. Venereol. Leprol. 2019, 85, 326–329. [Google Scholar] [PubMed]
- Georgescu, S.R.; Tampa, M.; Mitran, M.I.; Mitran, C.I.; Sarbu, M.I.; Nicolae, I.; Matei, C.; Caruntu, C.; Neagu, M.; Popa, M.I. Potential pathogenic mechanisms involved in the association between lichen planus and hepatitis C virus infection. Exp. Ther. Med. 2019, 17, 1045–1051. [Google Scholar] [CrossRef] [PubMed]
- Qasim, S.F.; Jami, A.; Imran, P.; Mushtaque, R.; Khan, R.N. Frequency of Metabolic Syndrome in Chronic Hepatitis C Patients: Findings from a Lower Middle-Income Country. Cureus 2020, 12, e11975. [Google Scholar] [CrossRef] [PubMed]
- Montagnani, M.; Potenza, M.A.; Corsalini, M.; Barile, G.; Charitos, I.A.; de Giacomo, A.; Jirillo, E.; Colella, M.; Santacroce, L. Current View on How Human Gut Microbiota Mediate Metabolic and Pharmacological Activity of Panax ginseng. A Scoping Review. Endocr. Metab. Immune Disord. Drug Targets 2024. ahead of print. [Google Scholar] [CrossRef]
- Antonelli, A.; Ferrari, S.M.; Giuggioli, D.; Di Domenicantonio, A.; Ruffilli, I.; Corrado, A.; Fabiani, S.; Marchi, S.; Ferri, C.; Ferrannini, E.; et al. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. 1 and type 2 diabetes mellitus. World J. Diabetes 2014, 5, 586–600. [Google Scholar] [CrossRef]
- Tenório, J.R.; de Camargo, A.R.; Lemos, C.; Ortega, K.L. Oral lichen planus and HCV infection. Autops. Case Rep. 2020, 10, e2020210. [Google Scholar] [CrossRef] [PubMed]
- Priora, M.; Borrelli, R.; Parisi, S.; Ditto, M.C.; Realmuto, C.; Laganà, A.; Centanaro Di Vittorio, C.; Degiovanni, R.; Peroni, C.L.; Fusaro, E. Autoantibodies and Rheumatologic Manifestations in Hepatitis C Virus Infection. Biology 2021, 10, 1071. [Google Scholar] [CrossRef] [PubMed]
- Palazzi, C.; D’Amico, E.; D’Angelo, S.; Gilio, M.; Olivieri, I. Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis. World J. Gastroenterol. 2016, 22, 1405–1410. [Google Scholar] [CrossRef] [PubMed]
- Babiker, A.; Jeudy, J.; Kligerman, S.; Khambaty, M.; Shah, A.; Bagchi, S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J. Clin. Transl. Hepatol. 2017, 5, 343–362. [Google Scholar] [CrossRef] [PubMed]
- Matsumori, A.; Ohashi, N.; Nishio, R.; Kakio, T.; Hara, M.; Furukawa, Y.; Ono, K.; Shioi, T.; Hasegawa, K.; Sasayama, S. Apical hypertrophic cardiomyopathy and hepatitis C virus infection. Jpn. Circ. J. 1999, 63, 433–438. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.M.; Song, I.H. Hepatitis C virus infection in chronic kidney disease: Paradigm shift in management. Korean J. Intern. Med. 2018, 33, 670–678. [Google Scholar] [CrossRef] [PubMed]
- Palombo, S.B.; Wendel, E.C.; Kidd, L.R.; Yazdi, F.; Naljayan, M.V. MPGN and mixed cryoglobulinemia in a patient with hepatitis C—New treatment implications and renal outcomes. Clin. Nephrol. Case Stud. 2017, 5, 66–69. [Google Scholar] [CrossRef] [PubMed]
- Schamberg, N.J.; Lake-Bakaar, G.V. Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinica Manifestations, and New Therapies. Gastroenterol. Hepatol. 2007, 3, 695–703. [Google Scholar]
- Fabrizi, F.; Plaisier, E.; Saadoun, D.; Martin, P.; Messa, P.; Cacoub, P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am. J. Kidney Dis. 2013, 61, 623–637. [Google Scholar] [CrossRef]
- Smith, K.D.; Alpers, C.E. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr. Opin. Nephrol. Hypertens. 2005, 14, 396–403. [Google Scholar] [CrossRef]
- Gill, K.; Ghazinian, H.; Manch, R.; Gish, R. Hepatitis C virus as a systemic disease: Reaching beyond the liver. Hepatol. Int. 2016, 10, 415–423. [Google Scholar] [CrossRef] [PubMed]
- Wijarnpreecha, K.; Nissaisorakarn, P.; Sornprom, S.; Thongprayoon, C.; Thamcharoen, N.; Maneenil, K.; Podboy, A.J.; Cheungpasitporn, W. Hepatitis C infection and renal cell carcinoma: A systematic review and meta-analysis. World J. Gastrointest. Pathophysiol. 2016, 7, 314–319. [Google Scholar] [CrossRef]
- Chen, Y.P.; Cheng, H.; Rui, H.L.; Dong, H.R. Cryoglobulinemic vasculitis and glomerulonephritis: Concerns in clinical practice. Chin. Med. J. 2019, 132, 1723–1732. [Google Scholar] [CrossRef] [PubMed]
- Barsoum, R.S.; William, E.A.; Khalil, S.S. Hepatitis C and kidney disease: A narrative review. J. Adv. Res. 2017, 8, 113–130. [Google Scholar] [CrossRef] [PubMed]
- Angeletti, A.; Cantarelli, C.; Cravedi, P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front. Med. 2019, 6, 20. [Google Scholar] [CrossRef] [PubMed]
- Young, M.; Leslie, S.W. Renal Biopsy. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
- Huang, Y.; Pan, H.; Gao, Q.; Lv, P.; Xu, X.; Zhao, Z. The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populations. Sci. Rep. 2021, 11, 8689. [Google Scholar] [CrossRef] [PubMed]
- Reta, D.H.; Tessema, T.S.; Ashenef, A.S.; Desta, A.F.; Labisso, W.L.; Gizaw, S.T.; Abay, S.M.; Melka, D.S.; Reta, F.A. Molecular and Immunological Diagnostic Techniques of Medical Viruses. Int. J. Microbiol. 2020, 2020, 8832728. [Google Scholar] [CrossRef] [PubMed]
- Warkad, S.D.; Song, K.S.; Pal, D.; Nimse, S.B. Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies. Sensors 2019, 19, 4257. [Google Scholar] [CrossRef] [PubMed]
- Vetter, B.N.; Ongarello, S.; Tyshkovskiy, A.; Alkhazashvili, M.; Chitadze, N.; Choun, K.; Sokkab, A.; De Weggheleire, A.; Vanroye, F.; Reipold, E.I. Sensitivity and specificity of rapid hepatitis C antibody assays in freshly collected whole blood, plasma and serum samples: A multicentre prospective study. PLoS ONE 2020, 15, e0243040. [Google Scholar] [CrossRef] [PubMed]
- Shahid, I.; Alzahrani, A.R.; Al-Ghamdi, S.S.; Alanazi, I.M.; Rehman, S.; Hassan, S. Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics 2021, 11, 1253. [Google Scholar] [CrossRef]
- Wang, Y.; Jie, W.; Ling, J.; Yuanshuai, H. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection. J. Clin. Lab. Anal. 2021, 35, e23755. [Google Scholar] [CrossRef]
- Manso, C.F.; Bibby, D.F.; Lythgow, K.; Mohamed, H.; Myers, R.; Williams, D.; Piorkowska, R.; Chan, Y.T.; Bowden, R.; Ansari, M.A.; et al. Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. Front. Microbiol. 2020, 11, 576572. [Google Scholar] [CrossRef]
- Noppornpanth, S.; Sablon, E.; De Nys, K.; Truong, X.L.; Brouwer, J.; Van Brussel, M.; Smits, S.L.; Poovorawan, Y.; Osterhaus, A.D.; Haagmans, B.L. Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5’ untranslated regions. J. Clin. Microbiol. 2006, 44, 3969–3974. [Google Scholar] [CrossRef]
- World Health Organization. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. 2018. Available online: https://www.who.int/publications/i/item/9789241550345 (accessed on 1 March 2024).
- American Association of Liver Disease, Infectious Disease Society of America HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C (2022). Available online: https://www.hcvguidelines.org/treatment-naive (accessed on 5 May 2024).
- Ho, P.T.; Balzanelli, M.G.; Distratis, P.; Lazzaro, R.; Tran, D.K.; Nguyen, K.C.D.; Bui, T.M.; Nguyen, T.T.; Pham, S.T.; Nguyen, H.S.D.; et al. Characteristics of Hepatitis B Virus Genotype and Sub-Genotype in Hepatocellular Cancer Patients in Vietnam. Diagnostics 2022, 12, 2393. [Google Scholar] [CrossRef] [PubMed]
- Fabrizi, F.; Aghemo, A.; Fogazzi, G.B.; Moroni, G.; Passerini, P.; D’Ambrosio, R.; Messa, P. Acute tubular necrosis following interferon-based therapy for hepatitis C: Case study with literature review. Kidney Blood Press. Res. 2013, 38, 52–60. [Google Scholar] [CrossRef] [PubMed]
- Perry, C.M. Telaprevir: A review of its use in the management of genotype 1 chronic hepatitis C. Drugs 2012, 72, 619–641. [Google Scholar] [CrossRef]
- Das, D.; Pandya, M. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy. Mini Rev. Med. Chem. 2018, 18, 584–596. [Google Scholar] [CrossRef]
- Khalilieh, S.; Feng, H.P.; Hulskotte, E.G.; Wenning, L.A.; Butterton, J.R. Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: Focus on drug-drug interactions. Clin. Pharmacokinet. 2015, 54, 599–614. [Google Scholar] [CrossRef]
- Sacco, R.; Messina, V.; Gentilucci, U.V.; Adinolfi, L.E.; Ascione, A.; Barbarini, G.; Barlattani, A.; Cariti, G.; Cozzolongo, R.; Fimiani, B.; et al. Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: A large, field-practice study. Drugs Context 2020, 9, 2020-4-11. [Google Scholar]
- Ahmed, O.A.; Elsebaey, M.A.; Fouad, M.; Elkadeem, M.; Badawi, R.; Khayyal, A.; Soliman, S.; Negm, M.S.; Abd-Elsalam, S. Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection. Infect. Disord. Drug Targets. 2020, 20, 389–395. [Google Scholar]
- Terrault, N.A.; Zeuzem, S.; Di Bisceglie, A.M.; Lim, J.K.; Pockros, P.J.; Frazier, L.M.; Kuo, A.; Lok, A.S.; Shiffman, M.L.; Ben Ari, Z.; et al. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients with Hepatitis C Virus Infection and Factors Associated with Sustained Virologic Response. Gastroenterology 2016, 151, 1131–1140.e5. [Google Scholar] [CrossRef]
- Keating, G.M. Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection. Drugs 2016, 76, 1203–1211. [Google Scholar] [CrossRef]
- Kwo, P.; Gane, E.J.; Peng, C.Y.; Pearlman, B.; Vierling, J.M.; Serfaty, L.; Buti, M.; Shafran, S.; Stryszak, P.; Lin, L.; et al. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection. Gastroenterology 2017, 152, 164–175.e4. [Google Scholar] [CrossRef]
- Papaluca, T.; Roberts, S.K.; Strasser, S.I.; Stuart, K.A.; Farrell, G.; MacQuillan, G.; Dore, G.J.; Wade, A.J.; George, J.; Hazeldine, S.; et al. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics. Clin. Infect. Dis. 2021, 73, e3288–e3295. [Google Scholar] [CrossRef]
- Liu, C.H.; Chen, C.Y.; Su, W.W.; Tseng, K.C.; Lo, C.C.; Liu, C.J.; Chen, J.J.; Peng, C.Y.; Shih, Y.L.; Yang, S.S.; et al. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 2022, 71, 176–184. [Google Scholar] [CrossRef]
- Poordad, F.; Pol, S.; Asatryan, A.; Buti, M.; Shaw, D.; Hézode, C.; Felizarta, F.; Reindollar, R.W.; Gordon, S.C.; Pianko, S.; et al. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 2018, 67, 1253–1260. [Google Scholar] [CrossRef]
- Wei, L.; Wang, G.; Alami, N.N.; Xie, W.; Heo, J.; Xie, Q.; Zhang, M.; Kim, Y.J.; Lim, S.G.; Fredrick, L.M.; et al. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: Two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol. Hepatol. 2020, 5, 839–849. [Google Scholar] [CrossRef]
- Llaneras, J.; Riveiro-Barciela, M.; Lens, S.; Diago, M.; Cachero, A.; García-Samaniego, J.; Conde, I.; Arencibia, A.; Arenas, J.; Gea, F.; et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J. Hepatol. 2019, 71, 666–672. [Google Scholar] [CrossRef]
- Kumar, R.; Hsiang, J.C.; Tan, J.; Thurairajah, P.H. Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report. Clin. Mol. Hepatol. 2019, 25, 326–330. [Google Scholar] [CrossRef] [PubMed]
- Sandmann, L.; Schulte, B.; Manns, M.P.; Maasoumy, B. Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. Visc. Med. 2019, 35, 161–170. [Google Scholar] [CrossRef]
- European Association for the Study of the Liver. Clinical Practice Guidelines Panel: EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020, 73, 1170–1218. [CrossRef] [PubMed]
- Park, H.; Wang, W.; Henry, L.; Nelson, D.R. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients with Chronic Hepatitis C in the United States. Hepatology 2019, 69, 1032–1045. [Google Scholar] [CrossRef]
- Salvatierra, K.; Fareleski, S.; Forcada, A.; López-Labrador, F.X. Hepatitis C virus resistance to new specifically targeted antiviral therapy: A public health perspective. World J. Virol. 2013, 2, 6–15. [Google Scholar] [CrossRef]
- Tran, T.T. Hepatitis C Virus Standard of Care: A Rapid Evolution and Considerations for Acute Hepatitis C Virus. Clin. Liver Dis. 2018, 12, 130–132. [Google Scholar] [CrossRef]
- WHO. Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV. Available online: https://www.who.int/publications/i/item/9789240052710 (accessed on 1 May 2024).
- WHO. Update Recommendations on Semplificate Service Delivery and Diagnostics for Hepatitis C Infection. Available online: https://www.who.int/publications/i/item/9789240052697 (accessed on 1 May 2024).
- Nijhuis, M.; van Maarseveen, N.M.; Boucher, C.A. Antiviral resistance and impact on viral replication capacity: Evolution of viruses under antiviral pressure occurs in three phases. Handb. Exp. Pharmacol. 2009, 189, 299–320. [Google Scholar]
- Abdulla, M.; Ali, H.; Nass, H.; Khamis, J.; AlQamish, J. Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain. Hepatic Med. Evid. Res. 2019, 11, 69–78. [Google Scholar] [CrossRef]
- Herzer, K.; Gerken, G. Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J. Hepatol. 2015, 7, 532–538. [Google Scholar] [CrossRef]
- Bart, G.; Piccolo, P.; Zhang, L.; Jacobson, I.; Schaefer, R.A.; Kreek, M.J. Markers for hepatitis A, B and C in methadone-maintained patients: An unexpectedly high co-infection with silent hepatitis B. Addiction 2008, 103, 681–686. [Google Scholar] [CrossRef]
- Nonomura, A.; Tamori, A.; Hai, H.; Kozuka, R.; Fujii, H.; Uchida-Kobayashi, S.; Enomoto, M.; Kawada, N. Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed. Intern. Med. 2021, 60, 3441–3445. [Google Scholar] [CrossRef] [PubMed]
- Samuel, D.; Coilly, A. Management of patients with liver diseases on the waiting list for transplantation: A major impact to the success of liver transplantation. BMC Med. 2018, 16, 113. [Google Scholar] [CrossRef]
- Townsend, S.A.; Monga, M.A.; Nightingale, P.; Mutimer, D.; Elsharkawy, A.M.; Holt, A. Hepatitis C Virus Recurrence Occurs Earlier in Patients Receiving Donation after Circulatory Death Liver Transplant Grafts Compared with Those Receiving Donation after Brainstem Death Grafts. Transplant. Proc. 2017, 49, 2129–2134. [Google Scholar] [CrossRef]
- Dai, C.Y.; Chuang, W.L.; Yu, M.L. EASL recommendations on treatment of hepatitis C: Final update of the series—Some issues. J. Hepatol. 2021, 74, 473–474. [Google Scholar] [CrossRef] [PubMed]
- Saab, S.; Challita, Y.; Chen, P.H.; Jimenez, M.A.; Lee, A.D.; Saab, E.G.; Ahn, T.; Choi, G.; Durazo, F.A.; El-Kabany, M.M.; et al. Elimination of Hepatitis C in Liver Transplant Recipients. J. Clin. Transl. Hepatol. 2018, 6, 247–250. [Google Scholar] [CrossRef]
- Bailey, J.R.; Barnes, E.; Cox, A.L. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology 2019, 156, 418–430. [Google Scholar] [CrossRef]
- Belli, L.S.; Perricone, G.; Adam, R.; Cortesi, P.A.; Strazzabosco, M.; Facchetti, R.; Karam, V.; Salizzoni, M.; Andujar, R.L.; Fondevila, C.; et al. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J. Hepatol. 2018, 69, 810–817. [Google Scholar] [CrossRef] [PubMed]
- Hashmi, Z.Y.; Zia, M.Q.; Bajwa, A.; Ahmed, M.; Answer, N.; Raza, M.; Baqar, J.B. New drugs and new concerns: Gaining insight through Pharmacovigilance of direct acting Anti-Viral’s in chronic HCV patients. Pak. J. Med. Sci. 2021, 37, 299–304. [Google Scholar] [CrossRef]
- Zeng, H.; Li, L.; Hou, Z.; Zhang, Y.; Tang, Z.; Liu, S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int. J. Med. Sci. 2020, 17, 892–902. [Google Scholar] [CrossRef]
- Kauffman-Ortega, E.; Ruiz-Manriquez, J.; Olivas-Martinez, A.; Campos-Murguía, A.; Flores-García, N.C.; Márquez-Guillén, E.; López-Yáñez, S.; Sánchez-Ávila, F.; Toapanta-Yanchapaxi, L.; Paez-Zayas, V.M.; et al. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort. Arch. Med. Res. 2021, 52, 713–718. [Google Scholar] [CrossRef] [PubMed]
- Alghamdi, W.; Lotfy, K.; Weernink, C.; Alsolami, E.; Jevnikar, A.; Luke, P.; Skaro, A.; Qumosani, K.; Brahmania, M.; Marotta, P.; et al. Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: Ready for prime time. BMC Gastroenterol. 2022, 22, 34. [Google Scholar] [CrossRef]
- Inoue, T.; Nakayama, J.; Moriya, K.; Kawaratani, H.; Momoda, R.; Ito, K.; Iio, E.; Nojiri, S.; Fujiwara, K.; Yoneda, M.; et al. Gut Dysbiosis Associated with Hepatitis C Virus Infection. Clin. Infect. Dis. 2018, 67, 869–877. [Google Scholar] [CrossRef]
- Yang, X.; Mai, H.; Zhou, J.; Li, Z.; Wang, Q.; Lan, L.; Lu, F.; Yang, X.; Guo, B.; Ye, L.; et al. Alterations of the gut microbiota associated with the occurrence and progression of viral hepatitis. Front. Cell Infect. Microbiol. 2023, 13, 1119875. [Google Scholar] [CrossRef]
- Colella, M.; Charitos, I.A.; Ballini, A.; Cafiero, C.; Topi, S.; Palmirotta, R.; Santacroce, L. Microbiota revolution: How gut microbes regulate our lives. World J. Gastroenterol. 2023, 29, 4368–4383. [Google Scholar] [CrossRef] [PubMed]
- Ashour, Z.; Shahin, R.; Ali-Eldin, Z.; El-Shayeb, M.; El-Tayeb, T.; Bakr, S. Potential impact of gut Lactobacillus acidophilus and Bifidobacterium bifidum on hepatic histopathological changes in non-cirrhotic hepatitis C virus patients with different viral load. Gut Pathog. 2022, 14, 25. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Topi, S.; Gaxhja, E.; Charitos, I.A.; Colella, M.; Santacroce, L. Hepatitis C Virus: History and Current Knowledge. Gastroenterol. Insights 2024, 15, 676-707. https://doi.org/10.3390/gastroent15030049
Topi S, Gaxhja E, Charitos IA, Colella M, Santacroce L. Hepatitis C Virus: History and Current Knowledge. Gastroenterology Insights. 2024; 15(3):676-707. https://doi.org/10.3390/gastroent15030049
Chicago/Turabian StyleTopi, Skender, Elona Gaxhja, Ioannis Alexandros Charitos, Marica Colella, and Luigi Santacroce. 2024. "Hepatitis C Virus: History and Current Knowledge" Gastroenterology Insights 15, no. 3: 676-707. https://doi.org/10.3390/gastroent15030049